Recent advances in the treatment of immune-mediated infl ammatory diseases

Methods in Molecular Biology

Volumn 1371, Issue , 2016, Pages 143-155

  Tas, Sander W ^a   Baeten, Dominique L P ^a  

^a NONE

Author keywords

B cells; Immune mediated infl ammatory diseases; Signal transduction; Treatment

Indexed keywords

ATACICEPT; B LYMPHOCYTE GROWTH FACTOR; BELIMUMAB; CYTOKINE; EPRATUZUMAB; I KAPPA B; INEBILIZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; OCRELIZUMAB; OFATUMUMAB; RITUXIMAB; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TABALUMAB; TOFACITINIB; VELTUZUMAB; CD20 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ANTIBODY PRODUCTION; AUTOINFLAMMATORY DISEASE; B LYMPHOCYTE; CELL ACTIVATION; CELL MIGRATION; CELL SURVIVAL; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE MEDIATED INFLAMMATORY DISEASE; IMMUNE RESPONSE; INTRACELLULAR SIGNALING; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN TARGETING; TARGET CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, SURFACE; B-LYMPHOCYTES; HUMANS; INFLAMMATION; JANUS KINASES; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; PROTEIN KINASE INHIBITORS;

EID: 84946434469     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3139-2_9     Document Type: Chapter

References (77)

1. Edwards JC, Szczepanski L, Szechinski J et al (2004) Effi cacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572-2581
2. Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221-232
3. Looney RJ, Anolik J, Sanz I (2010) A perspective on B-cell-targeting therapy for SLE. Mod Rheumatol 20:1-10
4. Looney RJ, Anolik JH, Campbell D et al (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50:2580-2589
5. Smith V, Piette Y, van Praet JT et al (2013) Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 40:52-57
6. Meijer JM, Meiners PM, Vissink A et al (2010) Effectiveness of rituximab treatment in primary Sjogren’s syndrome: a randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 62:960-968
7. Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with rituximab in relapsingremitting multiple sclerosis. N Engl J Med 358:676-688
8. Bluml S, McKeever K, Ettinger R, Smolen J, Herbst R (2013) B-cell targeted therapeutics in clinical development. Arthritis Res Ther 15(Suppl 1):S4
9. Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9:425-437
10. Castillo J, Milani C, Mendez-Allwood D (2009) Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin Investig Drugs 18:491-500
11. Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ (2011) Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebocontrolled clinical trial. Ann Rheum Dis 70:2119-2125
12. Ostergaard M, Baslund B, Rigby W et al (2010) Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 62:2227-2238
13. Sorensen PS, Lisby S, Grove R et al (2014) Safety and effi cacy of ofatumumab in relapsingremitting multiple sclerosis: a phase 2 study. Neurology 82:573-581
14. Kausar F, Mustafa K, Sweis G et al (2009) Ocrelizumab: a step forward in the evolution of B-cell therapy. Expert Opin Biol Ther 9:889-895
15. Rigby W, Tony HP, Oelke K et al (2012) Safety and effi cacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a fortyeight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 64:350-359
16. Tak PP, Mease PJ, Genovese MC et al (2012) Safety and effi cacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 64:360-370
17. Mysler EF, Spindler AJ, Guzman R et al (2013) Effi cacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 65:2368-2379
18. Kappos L, Li D, Calabresi PA et al (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378:1779-1787
19. Liebman HA, Saleh MN, Bussel JB et al (2013) Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. Br J Haematol 162:693-701
20. Goldenberg DM, Morschhauser F, Wegener WA (2010) Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma 51:747-755
21. Tedder TF (2009) CD19: a promising B cell target for rheumatoid arthritis. Nat Rev Rheumatol 5:572-577
22. Yazawa N, Hamaguchi Y, Poe JC, Tedder TF (2005) Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci U S A 102: 15178-15183
23. Herbst R, Wang Y, Gallagher S et al (2010) B-cell depletion in vitro and in vivo with anafucosylated anti-CD19 antibody. J Pharmacol Exp Ther 335:213-222
24. Deiss A, Brecht I, Haarmann A, Buttmann M (2013) Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Rev Neurother 13:313-335
25. Dorner T, Shock A, Smith KG (2012) CD22 and autoimmune disease. Int Rev Immunol 31: 363-378
26. Tedder TF, Poe JC, Haas KM (2005) CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv Immunol 88:1-50
27. Carnahan J, Stein R, Qu Z et al (2007) Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 44: 1331-1341
28. Steinfeld SD, Tant L, Burmester GR et al (2006) Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren’s syndrome: an open-label phase I/II study. Arthritis Res Ther 8:R129
29. Wallace DJ, Kalunian K, Petri MA et al (2014) Effi cacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebocontrolled, multicentre study. Ann Rheum Dis 73:183-190
30. Wallace DJ, Gordon C, Strand V et al (2013) Effi cacy and safety of epratuzumab in patients with moderate/severe fl aring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford) 52:1313-1322
31. Avery DT, Kalled SL, Ellyard JI et al (2003) BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 112:286-297
32. Baker KP, Edwards BM, Main SH et al (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48:3253-3265
33. Navarra SV, Guzman RM, Gallacher AE et al (2011) Effi cacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721-731
34. Stohl W, Merrill JT, McKay JD et al (2013) Effi cacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol 40:579-589
35. Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F (2013) The BAFF/ APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 24:203-215
36. Davidson A (2010) Targeting BAFF in autoimmunity. Curr Opin Immunol 22:732-739
37. Genovese MC, Lee E, Satterwhite J et al (2013) A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 72:1453-1460
38. Stohl W (2014) Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets 18: 473-489
39. Gensicke H, Leppert D, Yaldizli O et al (2012) Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. CNS Drugs 26:11-37
40. Gatto B (2008) Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. Curr Opin Investig Drugs 9:1216-1227
41. Schneider P (2005) The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 17:282-289
42. Dall’Era M, Chakravarty E, Wallace D et al (2007) Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 56:4142-4150
43. van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J (2011) Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 63:1782-1792
44. Genovese MC, Kinnman N, de La BG, Pena RC, Tak PP (2011) Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-fi nding trial. Arthritis Rheum 63:1793-1803
45. Kappos L, Hartung HP, Freedman MS et al (2014) Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol 13:353-363
46. Fernandez L, Salinas GF, Rocha C et al (2013) The TNF family member APRIL dampens collagen-induced arthritis. Ann Rheum Dis 72:1367-1374
47. Arthur JS, Ley SC (2013) Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 13:679-692
48. Hammaker D, Firestein GS (2010) “Go upstream, young man”: lessons learned from the p38 saga. Ann Rheum Dis 69(Suppl 1):i77-i82
49. Hommes D, van den Blink B, Plasse T et al (2002) Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn’s disease. Gastroenterology 122:7-14
50. Dotan I, Rachmilewitz D, Schreiber S et al (2010) A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn’s disease. Gut 59:760-766
51. Salh B (2007) c-Jun N-terminal kinases as potential therapeutic targets. Expert Opin Ther Targets 11:1339-1353
52. Guma M, Firestein GS (2012) c-Jun N-terminal kinase in infl ammation and rheumatic diseases. Open Rheumatol J 6:220-231
53. Han Z, Boyle DL, Chang L et al (2001) c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in infl ammatory arthritis. J Clin Invest 108:73-81
54. Hayden MS, Ghosh S (2011) NF-kappaB in immunobiology. Cell Res 21:223-244
55. Vallabhapurapu S, Karin M (2009) Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 27:693-733
56. Tak PP, Firestein GS (2001) NF-kappaB: a key role in infl ammatory diseases. J Clin Invest 107:7-11
57. Tak PP, Gerlag DM, Aupperle KR et al (2001) Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial infl ammation. Arthritis Rheum 44:1897-1907
58. Tas SW, Vervoordeldonk MJ, Hajji N, May MJ, Ghosh S, Tak PP (2006) Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial infl ammation. Arthritis Res Ther 8:R86
59. Kwak JH, Jung JK, Lee H (2011) Nuclear factor-kappa B inhibitors; a patent review (2006-2010). Expert Opin Ther Pat 21: 1897-1910
60. Sehnert B, Burkhardt H, Wessels JT et al (2013) NF-kappaB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-kappaB in immune-mediated diseases. Proc Natl Acad Sci U S A 110: 16556-16561
61. Sun SC (2012) The noncanonical NF-kappaB pathway. Immunol Rev 246:125-140
62. Noort AR, van Zoest KP, Weijers EM et al (2014) NF-kappaB inducing kinase is a key regulator of infl ammation-induced and tumorassociated angiogenesis. J Pathol 234:375
63. Li K, McGee LR, Fisher B et al (2013) Inhibiting NF-kappaB-inducing kinase (NIK): discovery, structure-based design, synthesis, structureactivity relationship, and co-crystal structures. Bioorg Med Chem Lett 23:1238-1244
64. Shuai K, Liu B (2003) Regulation of JAKSTAT signalling in the immune system. Nat Rev Immunol 3:900-911
65. Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P (2008) Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 10:R14
66. Changelian PS, Flanagan ME, Ball DJ et al (2003) Prevention of organ allograft rejection by a specifi c Janus kinase 3 inhibitor. Science 302:875-878
67. Fleischmann R, Kremer J, Cush J et al (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367:495-507
68. Burmester GR, Blanco R, Charles-Schoeman C et al (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381:451-460
69. Sandborn WJ, Ghosh S, Panes J et al (2012) Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367:616-624
70. Boy MG, Wang C, Wilkinson BE et al (2009) Double-blind, placebo-controlled, doseescalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol 129:2299-2302
71. Smolen JS, Landewe R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492-509
72. Baeten DL, Kuchroo VK (2013) How Cytokine networks fuel infl ammation: interleukin-17 and a tale of two autoimmune diseases. Nat Med 19:824-825
73. Yeremenko N, Paramarta JE, Baeten D (2014) The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis. Curr Opin Rheumatol 26:361-370
74. Byrne H, Conroy PJ, Whisstock JC, O’Kennedy RJ (2013) A tale of two specifi cities: bispecifi c antibodies for therapeutic and diagnostic applications. Trends Biotechnol 31: 621-632
75. Rossi EA, Chang CH, Goldenberg DM (2014) Anti-CD22/CD20 Bispecifi c antibody with enhanced trogocytosis for treatment of Lupus. PLoS One 9:e98315
76. Grabiec AM, Reedquist KA (2013) The ascent of acetylation in the epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 9:311-318
77. Vojinovic J, Damjanov N, D’Urzo C et al (2011) Safety and effi cacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 63:1452-1458